1Reaen GM.Role of insulin resistance in human disease.Diabetes 1998,37(12):1595-1607.
2Haffner SM.D Agostino R,Mykkanen L.Insulin sensitivity in subjects with type 2 diabetes.Diabetes Care 1999,22:562-568.
3Gerich JE.The genetic basis of type 2 diabetes mellitus:impaired insulin secration versus impaired insulin sensitivity.Endocr Rev 1998,19(4):491-503.
4U.K.Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33).Lencet 1998,352:837-853.
5Untied Kindom Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet 1998,352:854-865.
6Tontonoz P.Nagy L,Alare JG,et al.PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.Cell 1998,93:241-252.
7Finegood DT,Mcarthur MD.Dunichand-Hcedl A ,et al.The PPAR-gamma agonist,rosiglitazone,reverses hyperiasulinemia and promotes growth of islet betz-cell mass.Diabetes 1998,47(suppl 1):A47.
8Lister CA.Boam D.Bretherton-Wat: D.et al.Rosiglitazone increases pancreatic islet area,number and insulin content but not insulin gene expression.Diabetokgia 1998,41(suppl 1):A169.
9Porter LE.Freed MI.Jones NP.et al.Rosiglitazone improves βcell function as easured by rpoinsulin/insulin ratio in patients with type 2 diabetes.Diabetes 2000,49(supl 1):A122.
